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The topic of peroxisome proliferator-activated receptors has been developed in the ﬁeld of hepatology allowing envisaging
therapeutic strategies for the most frequent chronic liver diseases such as chronic infection with hepatitis C virus (HCV).
PPARs contribute to wide physiological processes within the liver such as lipid/glucid metabolisms, inﬂammatory response, cell
diﬀerentiation, and cell cycle. In vitro experiments and animal studies showed that PPARα discloses anti-inﬂammatory property,
and PPARγ discloses anti-inﬂammatory, antiﬁbrogenic, and antiproliferative properties in the liver. Experimental and human
studies showed impaired PPARs expression and function during HCV infection. The available nonhepatotoxic agonists of PPARs
may constitute a progress in the therapeutic management of patients chronically infected with HCV.
Copyright © 2009 S´ ebastien Dharancy et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Chronic infection with the hepatitis C virus (HCV) is a
major cause of chronic liver disease worldwide, aﬀecting
about 3% of the population [1]. The natural history of
HCV infection is characterized by a high rate of progression
to chronic hepatitis leading, in at least 20% of cases, to
cirrhosis and ultimately to hepatocellular carcinoma [2,
3]. The precise mechanisms underlying HCV-related liver
injury are not well understood but involve a cell-mediated
immune response with lymphocytic inﬁltration leading to a
chronic inﬂammatory response and progressive scale ﬁbrosis
which are dependent on proinﬂammatory and ﬁbrogenic
mediators. HCV infection is also characterized by disruption
of lipid and glucid metabolisms leading to hepatocyte fat
accumulation (also called hepatic steatosis) and an increase
risk of diabetes [4–7] .T h e s el a t t e ra r eu n d e rd e p e n d e n c e ,a t
least in part, of peroxisome proliferator-activated receptors
functions.
Peroxisome proliferator-activated receptors (PPARs)
belong to the nuclear receptor superfamily and require
heterodimerization with receptor X for retinoids (RXR)
i no r d e rt of u n c t i o n[ 8]. The ﬁrst PPAR identiﬁed was
murine PPARα [9]. Since its description in 1990, a family
of homologous receptors has been identiﬁed in various
species. The PPAR family includes three subtypes: PPARα
(NR1C1), PPARβ (PPARδ or NR1C2), and PPARγ (NR1C3)
[10]. PPARα/γ, together with their obligate partner RXR,
are the three main nuclear receptors expressed in the
liver. These receptors contribute to the great diversity of
physiological processes in the liver, such as control of
lipid and glucid metabolisms, inﬂammatory responses, and
cellular diﬀerentiation and proliferation. PPAR activation
has been associated with anti-inﬂammatory and antiﬁbrotic
functions in the liver. In light of their multiple activities,
PPARs quickly became considered as therapeutic targets of
the most widespread human metabolic diseases (obesity,
diabetes, and atherosclerosis). The development of new2 PPAR Research
nonhepatotoxic ligands made it possible to use PPARs as
new therapeutic targets in hepatology. For these reasons,
recent discoveries in the ﬁeld of PPARs are of intense interest
not only to fundamental researchers but to clinicians as
well. This review will ﬁrst describe the main functions of
PPARswithintheliver.ThentheinteractionsbetweenPPARs
and HCV will be developed to provide a precise picture of




PPARα is strongly involved in the control of lipid and
lipoprotein metabolisms. PPARα−/− mice display minimal
accumulation of triglycerides in the liver under fed con-
ditions, but manifest an exaggerated steatotic response to
fasting [11]. Moreover, PPARα−/− mice fed a high-fat diet
showed massive accumulation of lipids in the liver, high-
lighting itscrucialroleinlipid metabolism [12].Intracellular
fatty acid (FA) concentrations are controlled, in part, by
regulation of the FA import and export system. PPARs
control the uptake of FA in liver; for example, PPAR agonists
control expression of the FA transport protein (FATP-1)
responsible for FA transport across the cell membrane,
FA translocase (FAT/CD36), and the hepatic cytosolic FA
binding protein (L-FABP) involved in FA traﬃcking [13].
The absence of induction of FATP-1 and FAT/CD36 mRNA
in liver by PPARα activators has been well demonstrated
in PPARα−/− mice. PPARα and -γ also prevent the eﬄux
of FA by promoting their activation into fatty acyl CoA
thioesters by the acyl-CoA synthetase ACS [14, 15]. In
addition, PPARα stimulates activated FA catabolism by the
peroxisomal, microsomal, and mitochondrial β-oxidation
systems. It regulates the expression of genes coding for
enzymes such as acyl-CoA oxidase (AOX), the ﬁrst and
main enzyme in the classic peroxisomal β-oxidation system.
It also activates the transcription of genes encoding for
classical microsomal β-oxidation system cytochrome P450
CYP4A (A1 and A3) isoforms, and stimulates activated FA
catabolism by mitochondrial β-oxidation. It is generally
accepted that oxidation of long-chain FA is regulated at the
level of the liver carnitine palmitoyl-transferase I (LCPT1),
whose product catalyzes the initial step in long-chain FA
import into mitochondria. PPARα has been demonstrated
to aﬀect FA import into mitochondria by upregulating
expression of the LCPT1 gene [14]. Concerning PPARγ,
treatment of HepG2 with troglitazone, a synthetic agonist,
speciﬁcally increased recycling by peroxisomal β-oxidation
of C18 to C16 FAs, and the interconversion of long-chain
FAs was associated with reduced de novo lipogenesis. It is
conceivable that these eﬀects of troglitazone on oxidation,
interconversion,andsynthesis-saturatedFAplayamajorrole
in cellular energy metabolism, membrane lipid composition
and turnover [16].
It has been convincingly established that PPARα acti-
vation increases plasma HDL cholesterol and enhances
reverse cholesterol transport via the induction of hepatic
apolipoprotein A-I and apolipoprotein A-II expression in
human liver. Nevertheless, PPARα activators aﬀect HDL
metabolism in an opposite manner in rodents and humans.
While ﬁbrate treatment of rats lowers plasma HDL, an
increase is generally observed in humans; such an increase
in HDL plasma levels is related, at least in part, to
changes in apoAI and apoA-II gene expression in liver.
ApoA-I and apoA-II gene transcription is upregulated in
humans and repressed in rodents by PPARα activators.
Treatment of human primary hepatocytes with ﬁbrates
increases mRNA levels and secretion of apoA-I. Moreover,
in patients with familial combined hyperlipoproteinemia,




PPAR in the Liver
PPARαexertcatabolicfunctionthroughperoxisomal,micro-
somal, and mitochondrial β-oxydation pathways, and there-
fore allows the use of FA by hepatocytes as energetic
substrate.Thus, it degrades several lipid inﬂammatory medi-
ators (prostaglandins, leukotriens) using these metabolic
pathways [18, 19]. There are numerous experimental and
clinical evidences in favor of anti-inﬂammatory activity
of PPAR in the liver. PPARα and PPARγ were shown
to negatively interfere with the nuclear factor (NF)-κB,
signal transducers and activators of transcription (STAT),
and activating protein 1 (AP-1) signalling pathways in
primary hepatocyte cultures and monocytes/macrophages
[20, 21]. Delerive et al. showed that ﬁbrates, which are the
main synthetic agonists of PPARα induced the expression
of IκBα protein in primary human hepatocytes, whereas
neither IκB kinase activity nor the degradation rate of
IκBα was aﬀected. The consequence is that the downstream
inﬂammatory responses genes such as IL-2, IL-6, IL-8,
TNFα, and metalloproteases are inhibited [20]. PPARα can
also control hepatic inﬂammation by regulating hemostatic
factors and acute-phase response proteins in hepatocytes
[22].
T-lymphocytes, natural killer cells, and monocytes/
macrophages express signiﬁcant amount of PPARα and
γwhen activated, and they inhibit the production of inﬂam-
matory and immunomodulatory activity cytokines [23–28].
In lymphocytes, immunomodulatory activity is supported
by a decrease in nuclear factor of activated T-cells (NFAT)
activitywhichregulateIL-2promoter[23,29].PPARγ inhibit
the proliferation of T-lymphocytes and the production of
IFNγ,T N F α, and IL-2 [30].
Animal studies conﬁrmed the role of PPARα and
PPARγ in inﬂammation control showing that PPARα−/−
mice display a prolonged response to inﬂammation induced
by arachidonic acid or zymosan [31–33]. Interestingly,
PPARα−/− and PPARγ+/− mice displayed an exacerbated
sensibility to hepatitis in diﬀerent models of liver injury
[34, 35].PPAR Research 3
4. Antiﬁbrogenic Activitiesof PPAR in
the Liver
Hepatic stellate cells (HSCs) are the main cells responsible
for liver modulation, by producing the protein of the
extracellular matrix [36, 37]. In response to liver injury,
HSC changes from a quiescent to an activated phenotype.
This activation process includes a phenotypic change to a
myoﬁbroblast-like cell, an increased proliferation rate, loss
of retinoid stores, and increased production of extracellular
matrix proteins, chemokines, cytokines, and contractility.
Interestingly, HSC activation is associated with impaired
expression of PPARγ and with a decrease in binding to
the peroxisome proliferator response element (PPRE) in
vivo, whereas NFκB and AP-1 binding is increased. HSC
activation is reversed by treatment with PPARγ agonists
in vitro, suggesting antiﬁbrogenic activity [38, 39]. PPARγ
activationdose-dependentlyinhibitedHSCproliferationand
chemotaxis induced by platelet-derived growth factor. This
eﬀect was independent of changes in postreceptor signalling
or expression of c-fos and c-myc, and was associated with
inhibition of cell progression beyond the G1 phase. PPARγ
activation also resulted in complete inhibition of the expres-
sion of monocyte chemotactic protein (MCP1), a potent
chemoattractant for monocytes and T-lymphocytes [40].
All things considered, PPARγ activation in vitro resulted in
decreases in HSC proliferation, migration, and chemokine
expression, three pivotal actions relevant to the process of
liver wound healing and ﬁbrogenesis. A study performed
in a model of liver ﬁbrosis induced by dimethylnitrosamine
or carbon tetrachloride showed that oral administration of
pioglitazone or rosiglitazone reduces hepatic extracellular
matrix deposition and HSC activation [41]. PPARα ligands
may also have rescue eﬀects on hepatic ﬁbrosis. Using
thioacetamide models of liver cirrhosis, animals treated
with a diet containing one of the two PPARα ligands,
Wy-14 643 (WY) or fenoﬁbrate, displayed reduced hepatic
ﬁbrosis. PPARα ligands had an antiﬁbrotic action in the
thioacetamine model of liver cirrhosis, probably due to
an antioxidant eﬀect of enhanced catalase expression and
activity in the liver [42].
5. InteractionbetweenHCVand PPARs
Liver inﬂammation, hepatocyte fat accumulation, and dia-
betes are three pivotal hallmarks in the natural history
of chronic HCV infection which are at least in part
controlled by PPARs. Thus, it was tempting for several
teams to investigate whether PPARα/γ may be impaired
and/or nonfunctional, and might therefore play a role in the
physiopathology of HCV infection.
NumerousstudieshavedemonstratedthatPPARα/γ were
physiologically highly expressed by parenchymal hepatic
cells, where they play a pivotal anti-inﬂammatory and
metabolic role. Several teams have demonstrated, using in
vitroand ex vivo approaches, a decrease expression and
functional activity of PPARα in hepatocytes during HCV
infection, which may contribute to the pathogenesis of the
disease. (1) During chronic HCV infection in humans [43,
44], (2) in an experimental model of transgenic mouse [4],
and (3) in transfected hepatocytes expressing the capsid
protein of HCV [4, 43, 44]. These abnormalities may be
the consequence of viral capsid inhibiting transcriptional
activityofgenesinvolvedinlipidmetabolismofinfectedhost
cell [4, 43, 44].
In the same line, De Gottardi et al. showed that (1)
PPARγ expression was signiﬁcantly lower in genotype 3
compared with genotype 1 HCV infection and (2) steatosis
was associated to decreased levels of PPARγ in genotype
1 HCV infection. In this study, there was no signiﬁcant
relationship between PPARs mRNA levels and liver activity
or ﬁbrosis. The presences of steatosis and hepatitis C
virus genotype 3 were both associated with a signiﬁcant
downregulation of PPARs [44].
The ways in which impaired expression of PPARα/γ con-
tribute to the pathogenesis of HCV hepatitis are numerous.
As previously described, PPARα activators play a regulatory
role in the inﬂammatory response at the hepatic level by
inhibiting cytokines and acute-phase inﬂammatory protein
production by negatively interfering with NF-κB and AP-1
pathways. Clinical evidence for the anti-inﬂammatory role
of PPARα in the liver was provided by the characterization
of PPARα−/− m i c ew h i c hw e r em o r es u s c e p t i b l et ov a r i o u s
hepatotoxic compounds and had delayed liver regeneration
compared to their wild-type littermates. A recent study also
demonstrated that activation of PPARα limits the expression
of the TH1 cytokine proﬁle and TNFα production by
human CD4-positive T-cells, a cytokine pattern known to
substantially contribute to HCV pathogenesis.
Preliminary human data reinforce interest in this topic.
Two pilot studies suggested therapeutic eﬀects of bezaﬁbrate,
an agonist of PPARα/β/γ, during chronic HCV infection. In
the ﬁrst open trial, 30 patients unresponsive to interferon
monotherapy were treated for 6 months with 400mg/day
[45]. At endpoint, viral load and liver enzymes were signiﬁ-
cantly decreased, suggesting anti-inﬂammatory and antiviral
activities of bezaﬁbrate. More recently, 7 patients received
400mg/day of bezaﬁbrate for 8 weeks. Once again, ALT,
AST, and viral load were lowered compared to baseline [46].
Takentogether,theseresultsmayargueinfavorofrestoration
of transcriptional activity of the hepatoprotective PPARα
and/or PPARγ receptors during chronic HCV infection.
Pioglitazone, an agonist of PPARγ, is currently evaluated in
patient with chronic HCV infection and insulin resistance
(http://clinicaltrials.gov/show/NCT00189163).
6. Conclusion
Chronic infection with HCV is a major cause of chronic
liver disease worldwide and is associated with chronic liver
inﬂammation, hepatocyte fat accumulation, and diabetes.
Nuclear hormone receptors PPARα and γ are involved in
the transduction of metabolic and nutritional signals into
transcriptional responses in order to maintain liver home-
ostasis. Evidence exists in favor of a decreased expression
and functional activity of PPARα/γ in hepatocytes during4 PPAR Research
HCV infection related to HCV core protein, suggesting
that HCV may have evolved strategies to prevent inducing,
or to overcome, an eﬃcient response by the host. This
decreased expression of PPARα/γ may be involved in the
pathogenesis of HCV infection through an alteration of
the protective eﬀects of these nuclear receptors against
hepatic inﬂammation and ﬁbrosis. Taken together, all these
considerations suggest that PPARα/γ may represent new
potential therapeutic targets in HCV infection.
Nomenclature:
PPAR: Peroxisome proliferator-activated receptor
RXR: Retinoid X receptor
HCV: Hepatitis C virus
FA: Fatty acid.
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